RNF34 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q969K3 |
Other Accession | Q6AYH3, Q99KR6, Q5E9J6, NP_079402.2, NP_919247.1 |
Reactivity | Human |
Predicted | Bovine, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 41641 Da |
Antigen Region | 283-311 aa |
Gene ID | 80196 |
---|---|
Other Names | E3 ubiquitin-protein ligase RNF34, 632- {ECO:0000269|PubMed:25012219, ECO:0000269|Ref13}, Caspase regulator CARP1, Caspases-8 and -10-associated RING finger protein 1, CARP-1, FYVE-RING finger protein Momo, RNF34 (HGNC:17297) |
Target/Specificity | This RNF34 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 283-311 amino acids from the C-terminal region of human RNF34. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | RNF34 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | RNF34 (HGNC:17297) |
---|---|
Function | E3 ubiquitin-protein ligase that regulates several biological processes through the ubiquitin-mediated proteasomal degradation of various target proteins. Ubiquitinates the caspases CASP8 and CASP10, promoting their proteasomal degradation, to negatively regulate cell death downstream of death domain receptors in the extrinsic pathway of apoptosis (PubMed:15069192). May mediate 'Lys-48'-linked polyubiquitination of RIPK1 and its subsequent proteasomal degradation thereby indirectly regulating the tumor necrosis factor-mediated signaling pathway (Ref.13). Negatively regulates p53/TP53 through its direct ubiquitination and targeting to proteasomal degradation (PubMed:17121812). Indirectly, may also negatively regulate p53/TP53 through ubiquitination and degradation of SFN (PubMed:18382127). Mediates PPARGC1A proteasomal degradation probably through ubiquitination thereby indirectly regulating the metabolism of brown fat cells (PubMed:22064484). Possibly involved in innate immunity, through 'Lys-48'-linked polyubiquitination of NOD1 and its subsequent proteasomal degradation (PubMed:25012219). |
Cellular Location | Cell membrane; Peripheral membrane protein. Endomembrane system {ECO:0000250|UniProtKB:Q6AYH3}; Peripheral membrane protein {ECO:0000250|UniProtKB:Q6AYH3}. Nucleus Nucleus speckle. Cytoplasm, cytosol |
Tissue Location | Ubiquitous. Detected in heart, brain, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, colon and leukocytes. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene contains a RINF finger, a motif known to be involved in protein-protein and protein-DNA interactions. This protein interacts with DNAJA3/hTid-1, which is a DnaJ protein reported to function as a modulator of apoptosis. Overexpression of this gene in Hela cells was shown to confer the resistance to TNF-alpha induced apoptosis, suggesting an anti-apoptotic function of this protein. This protein can be cleaved by caspase-3 during the induction of apoptosis. Alternatively spliced transcript variants encoding distinct isoforms have been reported.
References
Erlbruch, A., et al. Proteomics 10(16):2890-2900(2010)
Yang, W., et al. Cell Cycle 7(5):670-682(2008)
Yang, W., et al. J. Biol. Chem. 282(5):3273-3281(2007)
Konishi, T., et al. Mol. Cancer Ther. 4(5):743-750(2005)
Sasaki, S., et al. J. Exp. Clin. Cancer Res. 23(3):507-512(2004)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.